SCHEMBL18370115

SCHEMBL18370115

CN1C(=O)c2ccccc2N(S(C)(=O)=O)c2cc(Nc3ccc(O)cc3)ncc21

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ DCLK1 O15075 6/20 0.50
▸ BRD4 O60885 10/20 0.46
▸ MAPK7 Q13164 7/20 0.46
▸ LRRK2 Q5S007 6/20 0.45
▸ PIK3CD O00329 3/20 0.45
▸ AURKA O14965 3/20 0.45
▸ PIK3C2G O75747 3/20 0.45
▸ PIK3CG P48736 3/20 0.45
▸ AURKB Q96GD4 3/20 0.45
▸ BRDT Q58F21 1/20 0.44
▸ APP P05067 2/20 0.44
▸ KCNH2 Q12809 1/20 0.39
▸ PIK3CA P42336 1/20 0.38
▸ MTOR P42345 1/20 0.38
▸ PRKDC P78527 1/20 0.38
▸ NUAK1 O60285 1/20 0.37
▸ NR1H2 P55055 1/20 0.37
▸ NR1H3 Q13133 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17059741 0.77 BRD4 (0.78) DCLK1BRD4MAPK7LRRK2BRDT
SCHEMBL17059738 0.77 DCLK1 (0.45) DCLK1BRD4MAPK7LRRK2PIK3CD
SCHEMBL18369863 0.73 MAPK7 (0.55) DCLK1BRD4MAPK7LRRK2PIK3CD
SCHEMBL18370065 0.72 BRD4 (0.49) DCLK1BRD4MAPK7LRRK2PIK3CD
SCHEMBL17059944 0.71 LRRK2 (0.72) DCLK1BRD4MAPK7LRRK2KCNH2
SCHEMBL18369924 0.70 MAPK7 (0.59) DCLK1BRD4MAPK7LRRK2PIK3CD
SCHEMBL18369886 0.68 MAPK7 (0.57) DCLK1BRD4MAPK7LRRK2PIK3CD
SCHEMBL18369919 0.68 MAPK7 (0.56) DCLK1BRD4MAPK7LRRK2PIK3CD
SCHEMBL17059947 0.67 BRD4 (0.76) DCLK1BRD4MAPK7LRRK2PIK3CD
SCHEMBL18379253 0.67 BRD4 (0.76) DCLK1BRD4MAPK7LRRK2PIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170008888-A1 HETEROCYCLIC COMPOUNDS ACTIVX BIOSCIENCES, INC. 2017-01-12 — — US disclosed
US-20170008888-A1 HETEROCYCLIC COMPOUNDS ACTIVX BIOSCIENCES, INC. 2017-01-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170008888-A1 HETEROCYCLIC COMPOUNDS BET1, EP300, RBBP5 DCLK1 3272/4885BRD4 4/4885MAPK7 58/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback